6:27 PM
 | 
Oct 01, 2007
 |  BC Extra  |  Company News

Lev's Cinryze gets Priority Review

FDA accepted for filing and granted Priority Review to a BLA from LEVP for Cinryze for the acute treatment of hereditary angioedema (HAE)....

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >